Literature DB >> 26622835

Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer.

Xiaoming Song1, Chunhai Fu2, Xudong Yang1, Dongfeng Sun1, Xianqi Zhang1, Jiandong Zhang1.   

Abstract

Tripartite motif-containing 29 (TRIM29) is a member of the tripartite motif (TRIM) protein family. TRIM29 has been reported to be deregulated in a number of cancer types, suggesting the oncogenic function of TRIM29. However, its clinical significance in non-small cell lung cancer (NSCLC) has not been fully elucidated. In the present study, the TRIM29 expression status was investigated by immunohistochemical analysis in paraffin-embedded specimens obtained from 320 patients with surgically resected NSCLC, treated between 2000 and 2007. High TRIM29 expression was significantly associated with smoking (P=0.012), T stage (P=0.015) and M stage (P=0.003). Furthermore, elevated TRIM29 expression level was correlated with reduced overall (OS) and disease-free survival. In addition, high TRIM29 expression was an independent prognostic factor for OS [P=0.003, hazard ratio (HR)=2.102, 95% confidence interval (CI), 1.069-3.193]. In conclusion, these results suggest that TRIM29 may be a useful prognostic marker in NSCLC patients and a potential molecular target for NSCLC treatment.

Entities:  

Keywords:  TRIM29; biomarker; non-small cell lung cancer; prognosis

Year:  2015        PMID: 26622835      PMCID: PMC4579806          DOI: 10.3892/ol.2015.3623

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

Authors:  Lars Dyrskjøt; Mogens Kruhøffer; Thomas Thykjaer; Niels Marcussen; Jens L Jensen; Klaus Møller; Torben F Ørntoft
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 2.  TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation.

Authors:  Luisa M Napolitano; Germana Meroni
Journal:  IUBMB Life       Date:  2011-11-30       Impact factor: 3.885

3.  TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.

Authors:  Jin Liu; Bryan Welm; Ken M Boucher; Mark T W Ebbert; Philip S Bernard
Journal:  Am J Pathol       Date:  2011-12-02       Impact factor: 4.307

Review 4.  Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases.

Authors:  Cynthia Villarreal-Garza; Dolores de la Mata; Diego G Zavala; Eleazar O Macedo-Perez; Oscar Arrieta
Journal:  Clin Lung Cancer       Date:  2012-06-07       Impact factor: 4.785

5.  TRIM proteins and cancer.

Authors:  Shigetsugu Hatakeyama
Journal:  Nat Rev Cancer       Date:  2011-10-07       Impact factor: 60.716

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.

Authors:  Lidong Wang; Huibin Yang; Phillip L Palmbos; Gina Ney; Taylor Ann Detzler; Dawn Coleman; Jacob Leflein; Mary Davis; Min Zhang; Wenhua Tang; J Kevin Hicks; Corey M Helchowski; Jayendra Prasad; Theodore S Lawrence; Liang Xu; Xiaochun Yu; Christine E Canman; Mats Ljungman; Diane M Simeone
Journal:  Cancer Res       Date:  2014-01-27       Impact factor: 12.701

8.  Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer.

Authors:  Yoshimasa Kosaka; Hiroshi Inoue; Takahiro Ohmachi; Takeshi Yokoe; Toshifumi Matsumoto; Koshi Mimori; Fumiaki Tanaka; Masahiko Watanabe; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2007-06-28       Impact factor: 5.344

9.  Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.

Authors:  Alessandro D Santin; Fenghuang Zhan; Stefania Bellone; Michela Palmieri; Stefania Cane; Eliana Bignotti; Simone Anfossi; Murat Gokden; Donna Dunn; Juan J Roman; Timothy J O'Brien; Erming Tian; Martin J Cannon; John Shaughnessy; Sergio Pecorelli
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

Review 10.  Targeted therapies for non-small cell lung cancer.

Authors:  Wolfram C M Dempke; Tamas Suto; Martin Reck
Journal:  Lung Cancer       Date:  2009-11-14       Impact factor: 5.705

View more
  16 in total

1.  Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation.

Authors:  Jia Sun; Jing Yan; Huai-Yu Qiao; Fu-Ying Zhao; Chao Li; Jing-Yi Jiang; Bao-Qin Liu; Xiao-Na Meng; Hua-Qin Wang
Journal:  Oncogene       Date:  2019-09-09       Impact factor: 9.867

2.  TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2.

Authors:  Zhanyao Tan; Libing Song; Wenjiao Wu; Yanqing Zhou; Jinrong Zhu; Geyan Wu; Lixue Cao; Junwei Song; Jun Li; Wei Zhang
Journal:  Oncogene       Date:  2018-06-04       Impact factor: 9.867

3.  TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis.

Authors:  Ling Hao; Boyu Du; Xueyan Xi
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

4.  TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin.

Authors:  Weifeng Xu; Beibei Chen; Dianshan Ke; Xiaobing Chen
Journal:  Aging (Albany NY)       Date:  2020-07-08       Impact factor: 5.682

Review 5.  E3 Ubiquitin Ligase TRIM Proteins, Cell Cycle and Mitosis.

Authors:  Santina Venuto; Giuseppe Merla
Journal:  Cells       Date:  2019-05-27       Impact factor: 6.600

Review 6.  The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members.

Authors:  Michael A Mandell; Bhaskar Saha; Todd A Thompson
Journal:  Front Pharmacol       Date:  2020-03-11       Impact factor: 5.810

7.  Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.

Authors:  Shunxiang Luo; Ming Shen; Hui Chen; Weiwei Li; Cong Chen
Journal:  Mol Med Rep       Date:  2020-09-01       Impact factor: 2.952

8.  TRIM52 inhibits Japanese Encephalitis Virus replication by degrading the viral NS2A.

Authors:  Wenchun Fan; Mengge Wu; Suhong Qian; Yun Zhou; Huanchun Chen; Xiangmin Li; Ping Qian
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

9.  TRIM29 as a prognostic predictor for multiple human malignant neoplasms: a systematic review and meta-analysis.

Authors:  Chao Liang; Huiyu Dong; Chenkui Miao; Jundong Zhu; Jie Wang; Pu Li; Jie Li; Zengjun Wang
Journal:  Oncotarget       Date:  2017-12-22

10.  TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC.

Authors:  Ming Lou; Zhaojia Gao; Tao Zhu; Xiaoliang Mao; Yeming Wang; Kai Yuan; Jichun Tong
Journal:  Oncol Lett       Date:  2019-12-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.